Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug holiday help women with rare uterine cancer?

NCT ID NCT03624244

Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether women with a rare, slow-growing uterine cancer (low-grade endometrial stromal sarcoma) can safely stop taking their hormone-blocking pills (aromatase inhibitors) after long-term use. Half the participants will stop the pills and half will continue, and researchers will track how long the cancer stays under control. The goal is to see if a break from medication can reduce side effects without worsening the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2019

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age≥18 years; * Histological confirmation of low grade ESS; * Locally advanced or metastatic disease at diagnosis or patient experiencing a tumor effraction during hysterectomy; * Treatment with aromatase inhibitors (Anastrozole or Exemestane or Letrozole ) initiated either: for at least 24 months (in patients with no residual disease or non-measurable disease at the last AI initiation) OR for at least 36 months (in patients with measurable disease at the last AI initiation); * Disease must be controlled at the time of the randomisation (objective response or stable disease) by the aromatase inhibitor initiated either for at least 24 or 36 months * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2 * Covered by a medical insurance; * Signed informed consent prior to any study-specific procedure. Exclusion Criteria: * Pregnant or breastfeeding woman; * Patient concurrently using other approved or investigational antineoplastic agents; * Major concurrent disease affecting cardiovascular system, liver, kidneys, hematopoietic system or else considered as clinically important by the investigator and that could be incompatible with patient's participation in this trial or would likely interfere with study procedures or results; * Prior history of malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 3 years; * Patients using prohibited concomitant and/or concurrent medications * Contra-indication according to SmPCs. * Patient requiring tutorship or curatorship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Low grade endometrial stromal sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial stromal tumor endometrioid stromal sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Low grade endometrial stromal sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    22 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP Hopîtal Cochin

    RECRUITING

    Paris, France

  • CHU Besançon

    RECRUITING

    Besançon, 25030, France

  • CHU Dupuytren

    RECRUITING

    Limoges, France

  • CHU Tours

    RECRUITING

    Tours, 37044, France

  • CHUSE

    RECRUITING

    Saint-Priest-en-Jarez, France

  • Centre Antoine Lacassagne

    NOT_YET_RECRUITING

    Nice, 06189, France

  • Centre François Baclesse

    RECRUITING

    Caen, 14076, France

  • Centre Henri Becquerel

    RECRUITING

    Rouen, France

  • Centre Jean Perrin

    RECRUITING

    Clermont-Ferrand, 63000, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69373, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, 59000, France

  • Hopital La Timone

    RECRUITING

    Marseille, 13005, France

  • Hopital La Timone

    RECRUITING

    Marseille, 13005, France

  • Hopital Pitié Salpétrière

    RECRUITING

    Paris, 75013, France

  • Hopital Privé de la Loire

    RECRUITING

    Saint-Etienne, 42020, France

  • ICO Centre René Gauducheau

    RECRUITING

    Saint-Herblain, 44805, France

  • Insitut Bergonié

    RECRUITING

    Bordeaux, France

  • Insitut Curie

    RECRUITING

    Paris, France

  • Institut Godinot

    RECRUITING

    Reims, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Institut Paoli Calmette

    RECRUITING

    Marseille, France

  • Institut de Cancérologie de Montpellier

    RECRUITING

    Montpellier, 34298, France